A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

References

• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–12. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59(1):237–250. doi:10.1146/annurev.med.59.060906.220345.
   PubMedGoogle Scholar
• Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, et al. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst. 2016;108. doi:10.1093/jnci/djw257.
   Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–7368. doi:10.1038/sj.onc.1206939.
   PubMed Web of Science ®Google Scholar
• Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck H-P, Weidmann E, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66. doi:10.1016/S1470-2045(15)00447-7.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Barate C, Motta M, Gini G, Goldaniga MC, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma. 2015;56(9):2637–2642. doi:10.3109/10428194.2015.1012714.
   PubMed Web of Science ®Google Scholar
• Smith KA, Lachman LB, Oppenheim JJ, Favata MF. The functional relationship of the interleukins. J Exp Med. 1980;151(6):1551–1556. doi:10.1084/jem.151.6.1551.
   PubMed Web of Science ®Google Scholar
• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4257):1007–1008. doi:10.1126/science.181845.
   PubMed Web of Science ®Google Scholar
• Dunne J, Lynch S, O’Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. 2001;167(6):3129–3138. doi:10.4049/jimmunol.167.6.3129.
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24(7):1169–1177. doi:10.1200/JCO.2005.03.6830.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107(6):2409–2414. doi:10.1182/blood-2005-06-2399.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093.
   PubMed Web of Science ®Google Scholar
• Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu Y-X. CTLA-4 limits anti-CD20–mediated tumor regression. Clin Cancer Res. 2017;23(1):193–203. doi:10.1158/1078-0432.CCR-16-0040.
   PubMed Web of Science ®Google Scholar
• Abes R, Gélizé E, Fridman WH, Teillaud J-L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116(6):926–934. doi:10.1182/blood-2009-10-248609.
   PubMed Web of Science ®Google Scholar
• Deligne C, Metidji A, Fridman W-H, Teillaud J-L. Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia. 2015;29(4):947–957. doi:10.1038/leu.2014.275.
   PubMed Web of Science ®Google Scholar
• Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res. 1995;55:2627–2634.
   PubMed Web of Science ®Google Scholar
• Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, et al. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and Phase I study. Clin Cancer Res. 2004;10(18):6101–6110. doi:10.1158/1078-0432.CCR-04-0525.
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10(7):2253–2264. doi:10.1158/1078-0432.CCR-1087-3.
   PubMed Web of Science ®Google Scholar
• Khan KD, Emmanouilides C, Benson DM Jr., Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, et al. A Phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res. 2006;12(23):7046–7053. doi:10.1158/1078-0432.CCR-06-1571.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010;59(11):1739–1744. doi:10.1007/s00262-010-0896-z.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Koval M, Poor M, Green LM, Daley J, Soiffer R, Ritz J, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma. Br J Haematol. 2002;117(4):828–834. doi:10.1046/j.1365-2141.2002.03535.x.
   PubMed Web of Science ®Google Scholar
• Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology. 2012;1(3):326–333. doi:10.4161/onci.18852.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, et al. Regulatory T cells and their prognostic relevance in hematologic malignancies. J Immunol Res. 2017;2017:1832968. doi:10.1155/2017/1832968.
   PubMed Web of Science ®Google Scholar
• Yang -Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8+ T-cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2006;66(20):10145–10152. doi:10.1158/0008-5472.CAN-06-1822.
   PubMed Web of Science ®Google Scholar
• Gunduz E, Sermet S, Musmul A. Peripheral blood regulatory T cell levels are correlated with some poor prognostic markers in newly diagnosed lymphoma patients. Cytometry B Clin Cytom. 2016;90(5):449–454. doi:10.1002/cyto.b.21330.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell. 2015;161(5):1035–1045. doi:10.1016/j.cell.2015.04.016.
   PubMed Web of Science ®Google Scholar
• Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, Fuente D, Leon K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol. 2013;190(12):6230–6238. doi:10.4049/jimmunol.1201895.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306. doi:10.1080/2162402X.2016.1277306.
   PubMed Web of Science ®Google Scholar
• Silva D-A, Yu S, Ulge UY, Spangler JB, Jude KM, Labao-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565(7738):186–191. doi:10.1038/s41586-018-0830-7.
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153–165. doi:10.1016/j.immuni.2010.08.004.
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26(1):453–479. doi:10.1146/annurev.immunol.26.021607.090357.
   PubMed Web of Science ®Google Scholar
• Boyman O, Krieg C, Homann D, Sprent J. Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci. 2012;69(10):1597–1608. doi:10.1007/s00018-012-0968-7.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–190. doi:10.1038/nri3156.
   PubMed Web of Science ®Google Scholar
• Rojas G, Carmenate T, Leon K. Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform. J Mol Recognit. 2015;28(4):261–268. doi:10.1002/jmr.2440.
   PubMed Web of Science ®Google Scholar
• Leon K, Garcia-Martinez K, Carmenate T, Rojas G. Combining computational and experimental biology to develop therapeutically valuable IL2 muteins. Semin Oncol. 2018;45(1–2):95–104. doi:10.1053/j.seminoncol.2018.04.001.
   PubMed Web of Science ®Google Scholar
• Blasius AL, Barchet W, Cella M, Colonna M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med. 2007;204(11):2561–2568. doi:10.1084/jem.20070991.
   PubMed Web of Science ®Google Scholar
• Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 2011;96(12):1822–1830. doi:10.3324/haematol.2011.047159.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood. 2009;114(9):1776–1783. doi:10.1182/blood-2008-12-192419.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4(5):511–527. doi:10.2217/imt.12.38.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ Jr., Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood. 2009;113(16):3809–3812. doi:10.1182/blood-2008-10-185280.
   PubMed Web of Science ®Google Scholar
• Michaud H-A, Eliaou J-F, Lafont V, Bonnefoy N, Gros L. Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology. 2014;3(9):e955684. doi:10.4161/21624011.2014.955684.
   PubMed Web of Science ®Google Scholar
• Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10(2):207–217. doi:10.1586/1744666X.2014.875856.
   PubMed Web of Science ®Google Scholar
• Shi Y-X, Zhang X-S, Liu D-G, Li Y-Q, Guan -Z-Z, Jiang W-Q. CD4+CD25+T regulatory cells in peripheral blood of B-NHL patients with or without chemotherapy. Ai Zheng. 2004;23:597–601.
   PubMedGoogle Scholar
• Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature. 2012;484(7395):529–533. doi:10.1038/nature10975.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Restifo NP. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci Transl Med. 2009;1(11):11ps12. doi:10.1126/scitranslmed.3000302.
   PubMed Web of Science ®Google Scholar
• Taylor JG, Gribben JG. Microenvironment abnormalities and lymphomagenesis: immunological aspects. Semin Cancer Biol. 2015;34:36–45. doi:10.1016/j.semcancer.2015.07.004.
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2(1):240. doi:10.1038/ncomms1239.
   PubMedGoogle Scholar
• Ding Z-C, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH, Zhou G. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood. 2012;120(11):2229–2239. doi:10.1182/blood-2011-12-398321.
   PubMed Web of Science ®Google Scholar
• Hus I, Bojarska-Junak A, Kaminska M, Dobrzynska-Rutkowska A, Szatan K, Szymczyk A, Kukielka-Budny B, Szczepanek D, Rolinski J. Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin’s lymphoma. Oncol Lett. 2017;14(6):7957–7964. doi:10.3892/ol.2017.7232.
   PubMed Web of Science ®Google Scholar
• Zhong W, Xu X, Zhu Z, Yang L, Du H, Xia Z, Yuan Z, Xiong H, Du Q, Wei Y, et al. Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol. 2018;52(5):1528–1538. doi:10.3892/ijo.2018.4299.
   PubMed Web of Science ®Google Scholar
• Lu T, Yu S, Liu Y, Yin C, Ye J, Liu Z, Ma D, Ji C, Bertolini F. Aberrant circulating Th17 cells in patients with B-cell non-Hodgkin’s lymphoma. PLoS One. 2016;11(1):e0148044. doi:10.1371/journal.pone.0148044.
   PubMed Web of Science ®Google Scholar
• Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008;123(3):326–338. doi:10.1111/j.1365-2567.2007.02719.x.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar